The committee met to discuss ibrutinib for treating Waldenstrom’s macroglobulinaemia on 15 November 2016. The provisional/draft recommendation that the committee has made requires that the Institute conducts further work before the documentation can be issued. This is to ensure that the recommendation can be implemented once the guidance has been published.
We will notify you in due course when we are ready to issue documentation